Mini Review Open Access
Volume 7 | Issue 1 | DOI: https://doi.org/10.33696/cancerimmunol.7.100
Immunotherapy in MSS/pMMR Metastatic Colorectal Cancer – Insights from the KEYNOTE-651
Ruoyu Miao1, Richard D. Kim2,*
- 1Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- 2Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Corresponding Author
Richard D. Kim, richard.kim@moffitt.org
Received Date: October 03, 2024
Accepted Date: November 02, 2024
Miao R, Kim RD. Immunotherapy in MSS/pMMR Metastatic Colorectal Cancer – Insights from the KEYNOTE-651. J Cancer Immunol. 2025;7(1):15-19.
Copyright: © 2025 Miao R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Microsatellite stable (MSS)/mismatch repair-proficient (pMMR) colorectal cancer (CRC) accounts for the majority of CRC cases and generally respond poorly to immunotherapy alone. This mini-review integrates findings from the KEYNOTE-651 study with current knowledge of frontline immunotherapy in MSS/pMMR metastatic CRC and explores the implications for clinical practice and future research directions.
Keywords
Chemotherapy, Colorectal cancer , Immunotherapy, KEYNOTE-651, Tumors
Recommended Articles
Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Searching for Easy Reliable Prognostic Parametres in Colorectal Cancer Patients Evaluation
Tumor node metastasis (TNM) staging system is the most useful method in predicting prognosis of colorectal cancer (CRC), the third most common cause of death worldwide, even if other biological markers are currently under evaluation to assess their role in affecting CRC outcome and planning the best tailored therapeutic approach. Several molecular factors are being demonstrated to be effective in influencing both overall survival (OS) and disease-free survival (DFS) in CRC, acting on different aspects of tumor promoting and progression.
Deubiquitinase as Potential Targets for Cancer Immunotherapy
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
The Effect of Glucocorticoids on Angiogenesis in the Treatment of Solid Tumors
Glucocorticoids (GCs) are defined by their role in maintaining glucose homeostasis and natural GCs are a class of corticosteroids secreted by the adrenal cortex. Cortisol is the most important natural GC in humans. Cellular cortisol levels are regulated by the tissue-specific metabolic enzymes 11β-hydroxysteroid dehydrogenase 1 and 2 (11β-HSD 1 and 2); 11β-HSD 1 converts inactive cortisone to active cortisol, while 11β-HSD 2 has the opposite function.
Role of the Gut Microbiome in the Modulation of Cancer Immunotherapy Response
The gut microbiome or gut flora is a vast community of microorganisms such as bacteria, viruses, protozoa, and fungi that inhabit the digestive tract of the human and other animals. In the human body, bacterial species colonize into the oral cavity, skin, vagina, and placenta, however, the largest population of microorganisms resides in the intestine. The majority of gut microbiota belong to the phyla Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.